Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention.
Marquis-Gravel G, Boivin-Proulx LA, Huang Z, Zelenkofske SL, Lincoff AM, Mehran R, Steg PG, Bode C, Alexander JH, Povsic TJ. Marquis-Gravel G, et al. Among authors: zelenkofske sl. J Am Heart Assoc. 2023 Jan 3;12(1):e025666. doi: 10.1161/JAHA.122.025666. Epub 2022 Dec 30. J Am Heart Assoc. 2023. PMID: 36583436 Free PMC article. Clinical Trial.
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.
Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, Bode C, Buller CE, Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeymer U, Natarajan M, Delarche N, Zelenkofske SL, Becker RC, Alexander JH; RADAR Investigators. Povsic TJ, et al. Among authors: zelenkofske sl. Eur Heart J. 2013 Aug;34(31):2481-9. doi: 10.1093/eurheartj/ehs232. Epub 2012 Aug 2. Eur Heart J. 2013. PMID: 22859796 Free PMC article. Clinical Trial.
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. Povsic TJ, et al. Among authors: zelenkofske sl. Cardiovasc Drugs Ther. 2017 Aug;31(4):445-458. doi: 10.1007/s10557-017-6739-9. Cardiovasc Drugs Ther. 2017. PMID: 28735360 Review.
Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes.
Staudacher DL, Putz V, Heger L, Reinöhl J, Hortmann M, Zelenkofske SL, Becker RC, Rusconi CP, Bode C, Ahrens I. Staudacher DL, et al. Among authors: zelenkofske sl. Eur Heart J Acute Cardiovasc Care. 2019 Sep;8(6):520-526. doi: 10.1177/2048872617703065. Epub 2017 Apr 13. Eur Heart J Acute Cardiovasc Care. 2019. PMID: 28403626
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.
Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, Huang Z, Sailstad J, Armstrong PW, Steg PG, Bode C, Becker RC, Alexander JH, Adkinson NF, Levinson AI; REGULATE-PCI Investigators. Povsic TJ, et al. Among authors: zelenkofske sl. J Allergy Clin Immunol. 2016 Dec;138(6):1712-1715. doi: 10.1016/j.jaci.2016.04.058. Epub 2016 Jul 14. J Allergy Clin Immunol. 2016. PMID: 27522158 No abstract available.
Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.
Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP, Hershfield MS. Ganson NJ, et al. Among authors: zelenkofske sl. J Allergy Clin Immunol. 2016 May;137(5):1610-1613.e7. doi: 10.1016/j.jaci.2015.10.034. Epub 2015 Dec 11. J Allergy Clin Immunol. 2016. PMID: 26688515 Free PMC article. No abstract available.
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.
Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH; REGULATE-PCI Investigators. Lincoff AM, et al. Among authors: zelenkofske sl. Lancet. 2016 Jan 23;387(10016):349-356. doi: 10.1016/S0140-6736(15)00515-2. Epub 2015 Nov 5. Lancet. 2016. PMID: 26547100 Clinical Trial.
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study.
Povsic TJ, Vavalle JP, Alexander JH, Aberle LH, Zelenkofske SL, Becker RC, Buller CE, Cohen MG, Cornel JH, Kasprzak JD, Montalescot G, Fail PS, Sarembock IJ, Mehran R; RADAR Investigators. Povsic TJ, et al. Among authors: zelenkofske sl. EuroIntervention. 2014 Aug;10(4):431-8. doi: 10.4244/EIJY14M06_01. EuroIntervention. 2014. PMID: 24929350 Free article. Clinical Trial.
18 results